MDR1-P-glycoprotein (ABCB1)-mediated disposition of amyloid-β peptides: implications for the pathogenesis and therapy of Alzheimer's disease.
The accumulation of neurotoxic amyloid-β (Aβ) peptides within the brain represents a hallmark of Alzheimer's disease (AD). It is proposed to be partly due to reduced elimination of Aβ from the brain into the blood. Diverse mechanisms of Aβ clearance out of the brain have been suggested. As discussed here, several lines of evidence suggest a significant role of the MDR1-P-glycoprotein (ABCB1), which is a major component of the blood-brain barrier (BBB).